Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

BACKGROUND: STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year interim analysis was to determine the effectiveness of nata...

Descripción completa

Detalles Bibliográficos
Autores principales: Perumal, Jai, Fox, Robert J., Balabanov, Roumen, Balcer, Laura J., Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, Lily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555913/
https://www.ncbi.nlm.nih.gov/pubmed/31176355
http://dx.doi.org/10.1186/s12883-019-1337-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555913/
https://www.ncbi.nlm.nih.gov/pubmed/31176355
http://dx.doi.org/10.1186/s12883-019-1337-z

Ejemplares similares